^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microbiome modulator

    Related drugs:
    5d
    COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Massachusetts General Hospital | Trial completion date: Dec 2027 --> Aug 2028 | Trial primary completion date: Dec 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    12d
    Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)
    P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Oct 2028 | Trial primary completion date: May 2027 --> Oct 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Cdactin-O (CBM588)
    16d
    Nucleoporin TPR integrates MAPK signaling with mitogen-induced transcriptional programs. (PubMed, Cell Death Dis)
    Using a novel phospho-specific monoclonal antibody, we show that TPR is phosphorylated at Ser2155 following EGFR activation via the canonical RAS-RAF-MEK-ERK MAPK cascade, placing TPR downstream of MAPK pathway activation...Finally, immunohistochemical analysis reveals elevated TPR phosphorylation in serous ovarian carcinoma and heterogeneous phosphorylation patterns in triple-negative breast cancer, two tumor types frequently characterized by MAPK pathway hyperactivation. Together, these findings uncover a previously unappreciated role for TPR as a MAPK-responsive nuclear factor and support a model in which NPC-associated components fine-tune mitogen-induced transcriptional responses.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    20d
    StarFish-UC: Confirmatory Clinical Study in Active Ulcerative Colitis (clinicaltrials.gov)
    P2, N=204, Recruiting, MRM Health NV | Not yet recruiting --> Recruiting
    Enrollment open
    21d
    MPOH14: A medical research to evaluate if MaaT013 is safe and helps children and adolescent with GI-aGvHD after failed two prior therapies. (2025-524302-15-00)
    P1/2, N=6, Not yet recruiting, MaaT PHARMA
    New P1/2 trial
    |
    Jakafi (ruxolitinib) • Xervyteg (MaaT013)
    22d
    A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer. (PubMed, Front Immunol)
    The probiotic Clostridium butyricum strain MIYAIRI 588 (CBM588) improves response rates and overall survival in patients receiving immune checkpoint inhibitor (ICI) therapy for non-small cell lung cancer and metastatic renal cell carcinoma but the mechanism underlying this benefit remains unclear...Across the patient cohort, higher post-treatment frequencies of CD69+ Vδ2 T-cells were associated with improved survival and more favourable clinical outcomes. These findings provide a potential mechanism by which manipulation of the intestinal microflora might contribute to cancer prognosis through effects on immune effector cells with intrinsic anticancer properties.
    Journal • IO biomarker
    |
    CD69 (CD69 Molecule)
    |
    Cdactin-O (CBM588)
    23d
    A Phase 1b Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multiple Dose Safety and Tolerability Study of Daily Dosing of BL-001 for 12 Weeks in Adults with Obesity (ACTRN12626000061336)
    P1, N=48, Active, not recruiting, Bloom Science Australia Pty Ltd | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Trial initiation date
    26d
    KAN-004 for Immune-Related Diarrhea or Colitis (clinicaltrials.gov)
    P1, N=21, Recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Initiation date: Oct 2025 --> Mar 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    1m
    RESIST-PTSD: Microbiome Modulation With Prebiotics in PTSD and Cirrhosis (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Hunter Holmes Mcguire Veteran Affairs Medical Center | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    1m
    MIYAIRI 588: CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Cdactin-O (CBM588)
    1m
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)
    2ms
    The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator "WellBiome" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings. (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Hull University Teaching Hospitals NHS Trust
    New trial • HEOR